申请人:DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
公开号:US20220220096A1
公开(公告)日:2022-07-14
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).